Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (161-170 of 452) with videos related to

Pageof 46
Sort By:
Human Pathology|August 20, 2013
Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomasAlcides Chaux, Roula Albadine, Luciana Schultz, et al.
British Journal of Cancer|December 3, 2011
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumoursR Pili, B Salumbides, M Zhao, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
Environmental Science and Pollution Research International|September 20, 2014
Hygienization performances of innovative sludge treatment solutions to assure safe land spreadingC Levantesi, C Beimfohr, A R Blanch, et al.
Human Reproduction Update|October 2, 2009
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)A La Marca, G Sighinolfi, D Radi, et al.
BJU International|June 19, 2012
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancerJatinder Goyal, Philipp Nuhn, Peng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trialEli Rosenbaum, Marianna Zahurak, Victoria Sinibaldi, et al.
Biomedicines|February 27, 2026
Age- and Treatment-Related Patterns in Fatigue, Coping/Resilience, and Skeletal Muscle Bioenergetics (<sup>31</sup>P-MRS τPCr) in Cancer Survivors: Exploratory Pilot AnalysisNada Lukkahatai, Susan Grayson, Michael A Carducci, et al.
La Radiologia Medica|April 1, 1997
[Fetal biliary lithiasis: ultrasonographic diagnosis and clinical interpretation. Report of 3 cases]A Agnifili, A Carducci, G Biasini, et al.
BJU International|February 18, 2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelPhilipp Nuhn, Ajay M Vaghasia, Jatinder Goyal, et al.
Pageof 46

Showing results (161-170 of 452) with videos related to

Sort By:
Pageof 46
Human Pathology|August 20, 2013
Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomasAlcides Chaux, Roula Albadine, Luciana Schultz, et al.
British Journal of Cancer|December 3, 2011
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumoursR Pili, B Salumbides, M Zhao, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
Environmental Science and Pollution Research International|September 20, 2014
Hygienization performances of innovative sludge treatment solutions to assure safe land spreadingC Levantesi, C Beimfohr, A R Blanch, et al.
Human Reproduction Update|October 2, 2009
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)A La Marca, G Sighinolfi, D Radi, et al.
BJU International|June 19, 2012
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancerJatinder Goyal, Philipp Nuhn, Peng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trialEli Rosenbaum, Marianna Zahurak, Victoria Sinibaldi, et al.
Biomedicines|February 27, 2026
Age- and Treatment-Related Patterns in Fatigue, Coping/Resilience, and Skeletal Muscle Bioenergetics (<sup>31</sup>P-MRS τPCr) in Cancer Survivors: Exploratory Pilot AnalysisNada Lukkahatai, Susan Grayson, Michael A Carducci, et al.
La Radiologia Medica|April 1, 1997
[Fetal biliary lithiasis: ultrasonographic diagnosis and clinical interpretation. Report of 3 cases]A Agnifili, A Carducci, G Biasini, et al.
BJU International|February 18, 2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelPhilipp Nuhn, Ajay M Vaghasia, Jatinder Goyal, et al.
Pageof 46